Welcome to our dedicated page for Nls Pharmaceutics news (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on Nls Pharmaceutics stock.
NLS Pharmaceutics Ltd (NLSP) delivers cutting-edge therapies for central nervous system disorders through innovative platforms like its dual orexin receptor agonist (DOXA) technology. This page provides essential updates for stakeholders tracking clinical developments, strategic partnerships, and regulatory milestones in neuropharmaceutical research.
Access verified press releases and analysis on NLSP's progress in addressing narcolepsy, neurodegenerative diseases, and cognitive disorders. Our curated news collection covers clinical trial results, intellectual property developments, and financial performance updates critical for informed decision-making.
Key content includes updates on the Kadimastem merger's therapeutic pipeline expansion, DOXA platform validation studies, and collaborative research initiatives. Investors will find timely reports on funding rounds, patent approvals, and preclinical data disclosures.
Bookmark this page for consolidated access to NLSP's latest advancements in CNS therapy development. Regularly updated to reflect material events and scientific breakthroughs, it serves as your primary resource for understanding the company's position in competitive biopharmaceutical markets.
NLS Pharmaceutics (NASDAQ:NLSP) has announced the closing of a private placement offering, raising $3.2 million through the issuance of 806,452 common shares and warrants at $3.97 per unit. The company also closed a debt purchase agreement, converting $4.0 million of debt into 806,452 convertible preferred shares at $4.96 each.
Additionally, NLS believes it has regained compliance with Nasdaq's minimum bid price requirement and expects to meet the stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The securities were offered under exemptions from registration requirements and have not been registered under the Securities Act.
NLS Pharmaceutics (Nasdaq:NLSP) announced a 1-for-40 reverse share split of its common shares, expected to be implemented on September 27, 2024. The company's shares will continue trading on the Nasdaq Capital Market under the symbol 'NLSP' but with a new CUSIP Number. This decision was approved by shareholders on September 18, 2024.
Post-split, NLS's outstanding common shares will reduce from 46,880,000 to approximately 1,172,000. No fractional shares will be issued, with cash provided in lieu. The split will not significantly impact shareholders' ownership percentages or voting power. All outstanding options and warrants will be adjusted accordingly. VStock Transfer, will serve as the exchange agent for this process.
NLS Pharmaceutics and Kadimastem have announced a binding term sheet for a merger, creating a Nasdaq-traded biotechnology company focused on advancing Kadimastem's allogeneic cell therapy platform. The proposed transaction will result in Kadimastem becoming a wholly owned subsidiary of NLS, with Kadimastem's shareholders acquiring an 85% interest in NLS. The combined company is expected to operate under the name Kadimastem and trade on the Nasdaq Capital Market. Both companies have received commitments of support from shareholders representing over 40% of their respective outstanding shares. The merger aims to create a company with product candidates in advanced stages of clinical development, particularly in the areas of neurodegenerative diseases and potential diabetes cure.
NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company specializing in treatments for rare and complex CNS disorders, announced a registered direct offering of 3,277,750 common shares at $0.24 per share. This offering is expected to close around July 1, 2024, subject to customary conditions. Additionally, NLS will issue unregistered warrants for the same number of shares, exercisable immediately at $0.24 per share and expiring in five years. The gross proceeds of $786,660 will support working capital, R&D, and strategic expansion. H.C. Wainwright & Co. is acting as the exclusive placement agent.
NLS Pharmaceutics (NASDAQ:NLSP) has announced promising preclinical results from in vitro studies targeting alpha-synuclein (A53T mutation) to treat Parkinson's Disease (PD). Utilizing the 'Alpha-Synuclein (A53T) Genetic Cell-Based Agonist Neurite Outgrowth Assay' by Eurofins, various compounds demonstrated positive effects on neurite outgrowth, indicating potential neuronal health benefits.
AEX-23 showed significant OX1R agonist activity and positive neurite outgrowth. AEX-19 showed benefits at low concentrations, increasing CTSD activity and imparting neuroprotective effects. AEX-24 enhanced CTSD activity, suggesting a role in alpha-synuclein degradation.
NLS plans to develop AEX-230 and AEX-231, targeting cathepsins involved in neurodegenerative disorders. Further preclinical and in vivo studies are needed to optimize dosing and assess long-term safety and efficacy.
NLS Pharmaceutics announced that the Nasdaq Hearings Panel has granted the company an extension until October 14, 2024, to meet listing requirements for the Nasdaq Capital Market. The company must comply with a minimum bid price of $1.00 per share and maintain at least $2,500,000 in stockholders' equity, as per Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1). Previously, NLS received notification from Nasdaq that it failed to meet these criteria, prompting a hearing on June 4, 2024. Despite the extension, there are no guarantees that NLS will achieve compliance by the deadlines.
NLS Pharmaceutics, a clinical-stage biopharmaceutical company, has announced a new patent application for dual orexin receptor agonists (DOXA), developed with Aexon Labs, targeting narcolepsy and neurodegenerative diseases like Parkinson's. These non-sulfonamide compounds are designed to reduce side effects and improve patient safety. The molecules enhance neurotransmitter release and protect neuronal health by modulating orexin receptors and inhibiting cathepsin H (CTSH), offering potential therapeutic benefits for sleep regulation and neurodegeneration. This patent represents a significant advancement in addressing unmet medical needs in both narcolepsy and neurodegenerative diseases.
NLS Pharmaceutics announced promising results from study KO-874, presented at the American Society of Clinical Psychopharmacology. The study evaluated mazindol's neuroprotective effects in a narcoleptic-like rat model. Key findings showed that a 3 mg/kg dose of mazindol significantly mitigated circadian activity reduction caused by OX-B-SAP lesions and restored activity levels to normal. Lower doses were less effective. The study highlights mazindol's potential utility in treating disorders like narcolepsy. Further clinical development is supported by these results.
NLS Pharmaceutics (NASDAQ: NLSP) announced it received an additional staff determination letter from Nasdaq on May 22, 2024, notifying the company of its non-compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing. This additional delinquency serves as a separate basis for potential delisting. Previously, on April 19, 2024, NLS was informed of potential delisting due to failing to maintain a $1 bid price per share. The company has requested a hearing before a Nasdaq Hearings Panel, scheduled for June 4, 2024, to appeal the delisting determination and present its plans to regain compliance.
